Alkermes Plc (ALKS)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Alkermes Plc (ALKS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012268
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. The company’s proprietary products include Aristada, an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, the only once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It also grants license under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to wholesalers, specialty distributors and specialty pharmacies. The company also has a clinical pipeline of products that address CNS disorders such as multiple sclerosis, schizophrenia, depression and addiction. Alkermes is headquartered in Dublin, Ireland.

Alkermes Plc (ALKS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Alkermes Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Alkermes Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Alkermes Plc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Civitas Therapeutics Raises USD55 Million in Series C Financing 11
Partnerships 13
Reset Therapeutics Enters into Co-Development Agreement with Alkermes 13
Licensing Agreements 14
Biogen Enters into Licensing Agreement with Alkermes 14
Alkermes Enters into Licensing Agreement with Domain Therapeutics 15
Asset Transactions 16
Recro Pharma Acquires Certain Assets from Alkermes 16
Alkermes Plc – Key Competitors 18
Alkermes Plc – Key Employees 19
Alkermes Plc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Oct 26, 2017: Alkermes Reports Third Quarter 2017 Financial Results 21
Jul 27, 2017: Alkermes Reports Second Quarter 2017 Financial Results 23
Apr 27, 2017: Alkermes Reports First Quarter 2017 Financial Results 24
Feb 15, 2017: Alkermes Reports Financial Results for the Year Ended Dec. 31, 2016 and Provides Financial Expectations for 2017 25
Nov 02, 2016: Alkermes Reports Third Quarter 2016 Financial Results 27
Jul 28, 2016: Alkermes Reports Second Quarter 2016 Financial Results 28
Apr 28, 2016: Alkermes Reports First Quarter 2016 Financial Results 30
Feb 25, 2016: Alkermes Reports Financial Results for the Year Ended Dec. 31, 2015 and Provides Financial Expectations for 2016 31
Corporate Communications 33
May 30, 2017: Alkermes Appoints Craig Hopkinson, M.D., as Chief Medical Officer, and Senior Vice President, Clinical Development and Medical Affairs 33
May 26, 2016: Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors 34
Government and Public Interest 35
Nov 09, 2017: Alkermes Reveals Recipients of the 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders 35
Nov 09, 2017: Alkermes Calls for Impartial National Review of Scientific Data Supporting the Use of FDA-Approved Treatment Options for Opioid Dependence 36
Sep 06, 2017: Alkermes Announces 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders 37
Nov 03, 2016: ALKERMES Inspiration Grants Awarded to Support People Affected by Mental Health and Substance Use Disorders 38
Sep 12, 2016: Alkermes Launches Competitive Grants Program to Support People Affected by Mental Health and Substance Use Disorders 39
Clinical Trials 40
Jun 29, 2017: Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of Schizophrenia 40
Jun 08, 2017: Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients 42
May 01, 2017: Alkermes Announces Completion of Patient Enrollment in Pivotal Antipsychotic Efficacy Study of ALKS 3831 for Schizophrenia 43
Oct 03, 2016: Alkermes Announces Initiation of Clinical Study Evaluating Metabolic Profile of ALKS 3831 for Treatment of Schizophrenia 44
May 25, 2016: Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 45
May 24, 2016: Alkermes to Present Data on ALKS 3831 at Upcoming American Society of Clinical Psychopharmacology Annual Meeting 46
Mar 28, 2016: Alkermes to Present Data on ALKS 3831 at Upcoming Schizophrenia International Research Society Conference 47
Feb 10, 2016: Alkermes Announces Initiation of Second Phase 3 Study of ALKS 3831 for Schizophrenia 48
Jan 21, 2016: Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive Disorder 49
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Alkermes Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Alkermes Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Alkermes Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Alkermes Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Civitas Therapeutics Raises USD55 Million in Series C Financing 11
Reset Therapeutics Enters into Co-Development Agreement with Alkermes 13
Biogen Enters into Licensing Agreement with Alkermes 14
Alkermes Enters into Licensing Agreement with Domain Therapeutics 15
Recro Pharma Acquires Certain Assets from Alkermes 16
Alkermes Plc, Key Competitors 18
Alkermes Plc, Key Employees 19
Alkermes Plc, Other Locations 20
Alkermes Plc, Subsidiaries 20

★海外企業調査レポート[Alkermes Plc (ALKS)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ameresco Inc (AMRC)-エネルギー分野:企業M&A・提携分析
    Summary Ameresco, Inc. (Ameresco) provides comprehensive energy services, including energy efficiency, infrastructure upgrades, asset sustainability and renewable energy solutions. It also offers energy infrastructure facility upgrade; and development, construction and operation of renewable energy …
  • Rebiotix Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Rebiotix Inc (Rebiotix), formerly MikrobEX Inc is a clinical stage biotechnology company that develops treatments for debilitating diseases. The company targets various disease conditions using drugs based on its microbiota restoration therapy platform. It lead product candidate RBX2660 is u …
  • Fremont Michigan InsuraCorp Inc.:企業の戦略・SWOT・財務情報
    Fremont Michigan InsuraCorp Inc. - Strategy, SWOT and Corporate Finance Report Summary Fremont Michigan InsuraCorp Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Voltamp Transformers Ltd (VOLTAMP):企業の財務・戦略的SWOT分析
    Voltamp Transformers Ltd (VOLTAMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • RadNet Inc (RDNT):医療機器:M&Aディール及び事業提携情報
    Summary RadNet Inc (RadNet) is a radiology company which specializes in diagnostic imaging services. The company offers freestanding, fixed-site diagnostic imaging services including imaging procedures magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nu …
  • IVERIC bio Inc (ISEE):企業の財務・戦略的SWOT分析
    Summary IVERIC bio Inc (IVERIC bio) formerly known as Ophthotech Corp, is a biopharmaceutical company that develops novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company’s products include Zimura, a complement inhibitor for stargardt di …
  • Miragen Therapeutics Inc (MGEN):製薬・医療:M&Aディール及び事業提携情報
    Summary Miragen Therapeutics, Inc. (Miragen) is a clinical stage biopharmaceutical company. It discovers and develops RNA-targeted therapeutics with a focus on microRNAs and their role in diseases. The company is developing its pipeline products for the treatment of Cutaneous T-Cell Lymphoma (CTCL), …
  • Black Hills Corporation (BKH):石油・ガス:M&Aディール及び事業提携情報
    Summary Black Hills Corp (BHC) is a vertically-integrated energy company which offers electricity and natural gas. The company produces, transmits, and distributes electricity; and sells natural gas on retail and wholesale basis. It generates electricity from natural gas, coal, diesel oil, and wind …
  • Keepmoat Ltd:企業の戦略的SWOT分析
    Keepmoat Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Flextronics International Ltd.:戦略・SWOT・企業財務分析
    Flextronics International Ltd. - Strategy, SWOT and Corporate Finance Report Summary Flextronics International Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Covanta Holding Corp (CVA):電力:M&Aディール及び事業提携情報
    Summary Covanta Holding Corp (Covanta) is a provider of sustainable waste and energy solutions. It generates electricity from its Energy-from-Waste (EfW); and recycles ferrous and non-ferrous metals through its subsidiaries. Its Energy-from-Waste (EfW) facilities convert more than 20 million tons of …
  • Pou Sheng International (Holdings) Ltd:戦略・SWOT・企業財務分析
    Pou Sheng International (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report Summary Pou Sheng International (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • The Kroger Co:企業の戦略・SWOT・財務情報
    The Kroger Co - Strategy, SWOT and Corporate Finance Report Summary The Kroger Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • OMV Petrom SA (SNP):電力:M&Aディール及び事業提携情報
    Summary OMV Petrom SA (Petrom), a subsidiary of OMV AG, is an integrated energy company that explores for, develops and produces crude oil and natural gas. The company processes and refines crude oil and sells refined products. It conducts power generation and has considerable wind energy operations …
  • Expedia Inc:企業のM&A・事業提携・投資動向
    Expedia Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Expedia Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • OraSure Technologies Inc (OSUR):医療機器:M&Aディール及び事業提携情報
    Summary OraSure Technologies Inc (OraSure) is a manufacturer and distributor of oral fluid specimen collection devices, diagnostic products and other medical devices. Its product portfolio encompasses infectious disease tests for the detection of antibodies for the HIV and Hepatitis C virus; Ebola v …
  • University of Southampton:製薬・医療:M&Aディール及び事業提携情報
    Summary University of Southampton (UOS) is an educational institution that offers education and research services. The institute provides educational programs in the fields of accounting and finance, acoustical engineering, aeronautics and astronautics, anthropology, archaeology, biochemistry, biolo …
  • Lazard Ltd:企業の戦略・SWOT・財務分析
    Lazard Ltd - Strategy, SWOT and Corporate Finance Report Summary Lazard Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • RegenxBio Inc (RGNX):企業の財務・戦略的SWOT分析
    RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Oncodesign SA (ALONC):企業の財務・戦略的SWOT分析
    Summary Oncodesign SA (Oncodesign) is a bio pharmaceutical company that discovers drugs to treat diseases with unmet medical needs. It is investigating LRRK2 inhibitor to treat Parkinson’s disease, RIPK2 inhibitor against autoimmune diseases, MNK1/2 inhibitor targeting cancer. The company offers dru …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆